Three Seasons Wealth LLC Acquires Shares of 8,016 Moderna, Inc. $MRNA

Three Seasons Wealth LLC purchased a new position in Moderna, Inc. (NASDAQ:MRNA) during the first quarter, HoldingsChannel reports. The firm purchased 8,016 shares of the company’s stock, valued at approximately $407,000.

Other institutional investors have also added to or reduced their stakes in the company. New Mexico Educational Retirement Board boosted its position in shares of Moderna by 1.9% during the fourth quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company’s stock valued at $463,000 after buying an additional 300 shares during the last quarter. Cromwell Holdings LLC boosted its holdings in shares of Moderna by 39.7% in the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after buying an additional 341 shares during the last quarter. IFP Advisors Inc grew its position in shares of Moderna by 5.4% during the 4th quarter. IFP Advisors Inc now owns 6,785 shares of the company’s stock valued at $200,000 after acquiring an additional 348 shares during the period. Empowered Funds LLC grew its holdings in Moderna by 2.6% during the fourth quarter. Empowered Funds LLC now owns 13,732 shares of the company’s stock valued at $405,000 after purchasing an additional 353 shares during the period. Finally, Deseret Mutual Benefit Administrators grew its stake in shares of Moderna by 16.9% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,640 shares of the company’s stock valued at $78,000 after acquiring an additional 382 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Stock Performance

NASDAQ:MRNA opened at $63.15 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $85.60. The stock’s 50 day simple moving average is $57.72 and its two-hundred day simple moving average is $50.73. The company has a market cap of $25.06 billion, a price-to-earnings ratio of -7.75 and a beta of 0.94.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The firm had revenue of $389.00 million for the quarter, compared to the consensus estimate of $236.37 million. During the same quarter in the prior year, the company posted ($2.52) earnings per share. The firm’s revenue was up 260.2% compared to the same quarter last year. As a group, equities analysts anticipate that Moderna, Inc. will post -6.48 earnings per share for the current fiscal year.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the transaction, the insider directly owned 67,468 shares of the company’s stock, valued at $3,373,400. This trade represents a 4.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Noubar Afeyan sold 9,263 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $46.84, for a total transaction of $433,878.92. Following the completion of the sale, the director owned 3,924 shares in the company, valued at approximately $183,800.16. This trade represents a 70.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 125,088 shares of company stock worth $6,193,713 in the last ninety days. Company insiders own 10.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. UBS Group reiterated a “neutral” rating on shares of Moderna in a research note on Tuesday, May 26th. Royal Bank Of Canada increased their target price on Moderna from $38.00 to $45.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a report on Thursday, June 18th. The Goldman Sachs Group upped their price target on Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Finally, Barclays increased their price objective on shares of Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a report on Thursday, April 2nd. Two research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $38.27.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.